Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies

Details

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly. The pathophysiology of CIDP is not completely understood but involves several humoral and cell-mediated mechanisms. Symptoms of CIDP include progressive limb weakness, usually with a predilection for proximal muscles, and sensory loss and are monophasic and progress for 8 weeks or more.

Target Audience:

Healthcare professionals specializing in: neurology, internal medicine; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in neurology; and those who otherwise commonly care for or clinically encounter patients with CIDP.

By the end of the session the participant will be able to:

• Describe the common clinical characteristics of CIDP.
• Identify components of electrodiagnostic criteria used to diagnose CIDP.
• Evaluate the present treatment options currently available for the management of CIDP.
• Identify new and emerging therapies for the treatment of CIDP.